Drug compliance for RX drugs, compounding, IV and peptides
Finding the RX Gaps for Medical Practices
What changed isn’t just enforcement; it’s the scale of compliance under the Drug Supply Chain Act (DSCSA). The FDA cannot inspect every practice in the country, and it has openly acknowledged this limitation. Therefore, it is not attempting to do so. Instead, the FDA is sharing data and aligning its enforcement efforts with state agencies, including Boards of Pharmacy and Health Departments, that already have inspectors in the field. This collaboration results in a compliance environment that is both federal and local, providing significantly more reach and faster consequences for violations than before.
At the same time, practices are being evaluated across multiple frameworks, including DSCSA drug sourcing and documentation, state-level handling and licensing, as well as compounding (503A/503B) decisions. Moreover, IV therapy practices are under scrutiny, particularly those that may trigger adulteration exposure, which poses risks not only to FDA compliance but also to the safety of RX and pharmaceutical drugs.
These are not separate risks; they converge on the same practice, the same documentation, and the same moment you’re asked to produce it during a medical audit.
What Happened?
What changed isn’t just enforcement; it’s the scale of compliance under the Drug Supply Chain Act (DSCSA). The FDA cannot inspect every practice in the country, and it has openly acknowledged this limitation. Therefore, it is not attempting to do so. Instead, the FDA is sharing data and aligning its enforcement efforts with state agencies, including Boards of Pharmacy and Health Departments, that already have inspectors in the field. This collaboration results in a compliance environment that is both federal and local, providing significantly more reach and faster consequences for violations than before.
At the same time, practices are being evaluated across multiple frameworks, including DSCSA drug sourcing and documentation, state-level handling and licensing, as well as compounding (503A/503B) decisions. Moreover, IV therapy practices are under scrutiny, particularly those that may trigger adulteration exposure, which poses risks not only to FDA compliance but also to the safety of RX and pharmaceutical drugs.
These are not separate risks; they converge on the same practice, the same documentation, and the same moment you’re asked to produce it during a medical audit.
About the Founder
James Strafuss
10-Question Risk Snapshot
Your exposure in under five minutes.
This assessment covers high-level risk across the Drug Supply Chain Act (DSCSA), FDA compliance, state inspections, compounding (503A/503B), and IV therapy/adulteration exposure related to RX and pharmaceutical drugs.
Instant scoring. No sales call. Just your risk profile.